A detailed history of Bridgeway Capital Management, LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 176,100 shares of PRLD stock, worth $209,559. This represents 0.01% of its overall portfolio holdings.

Number of Shares
176,100
Previous 123,600 42.48%
Holding current value
$209,559
Previous $470,000 22.55%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.07 - $6.37 $108,674 - $334,425
52,500 Added 42.48%
176,100 $364,000
Q1 2024

May 15, 2024

SELL
$2.68 - $4.84 $67,399 - $121,721
-25,149 Reduced 16.91%
123,600 $585,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $4.37 $188,942 - $488,566
111,800 Added 302.58%
148,749 $635,000
Q3 2022

Nov 14, 2022

SELL
$5.0 - $8.82 $50,000 - $88,200
-10,000 Reduced 21.3%
36,949 $244,000
Q2 2022

Aug 15, 2022

BUY
$4.0 - $7.55 $187,796 - $354,464
46,949 New
46,949 $245,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $43.3M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.